Key Points
- Ra Capital Management, L.P. (a Hemab director) bought 97,411 shares on May 5 at an average of $24.63 for $2,399,232.93, increasing its direct stake to 6,246,507 shares (a 1.58% rise) valued at about $153,851,467.41.
- Additional recent buys: Ra Capital also purchased 2,675,000 shares on May 4 at $18.00 ($48,150,000) and 68,018 shares on May 6 at $24.60 ($1,673,242.80), implying roughly $52.22 million in recent insider purchases.
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Get Free Report) Director Ra Capital Management, L.P. purchased 68,018 shares of Hemab Therapeutics stock in a transaction dated Wednesday, May 6th. The shares were bought at an average price of $24.60 per share, with a total value of $1,673,242.80. Following the completion of the acquisition, the director directly owned 6,314,525 shares of the company's stock, valued at approximately $155,337,315. This represents a 1.09% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Tuesday, May 5th, Ra Capital Management, L.P. purchased 97,411 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.63 per share, with a total value of $2,399,232.93.
- On Monday, May 4th, Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock. The shares were bought at an average price of $18.00 per share, with a total value of $48,150,000.00.
Hemab Therapeutics Stock Performance
Shares of NASDAQ:COAG opened at $25.01 on Thursday. Hemab Therapeutics Holdings, Inc. has a 1-year low of $23.48 and a 1-year high of $36.61.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
